José Trevejo, a co-founder and board member of SmartPharm Therapeutics, has been appointed CEO of the Cambridge, MA, company. Before joining SmartPharm, Trevejo was vice president, clinical development at Cyclerion Therapeutics, a spinout of Ironwood Pharmaceuticals (NASDAQ: [[ticker:IRWD]]). His experience also includes posts at Visterra, Genentech, and Vertex Pharmaceuticals (NASDAQ: [[ticker:VRTX]]). SmartPharm is developing non-viral gene therapies for rare diseases.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
